A Food and Drug Administration advisory panel voted Thursday to recommend that compounding pharmacies be allowed to manufacture the unapproved peptides BPC-157, KPV, TB-500, and MOTS-c. The decision represents a victory for health secretary Robert F. Kennedy Jr. and peptide proponents. A majority…
A Food and Drug Administration advisory committee recommended on Thursday that compounding pharmacies be permitted to manufacture the drugs BPC-157, KPV, TB-500, and MOTS-c. The vote marks a significant win for health secretary Robert F. Kennedy Jr. and advocates who have pushed for broader access to these little-researched but highly popular compounds.
The Pharmacy Compounding Advisory Committee PCAC is scheduled to vote on additional peptides on Friday. The recommendations are not binding on the FDA. The agency will ultimately decide whether to lift current restrictions on these substances, potentially making them more easily accessible to consumers who have turned to the drugs in hopes of improving their health despite a lack of robust scientific evidence.
A majority of the panelists who voted in favor of allowing compounding have financial connections to the peptide industry. The disclosure raises questions about potential conflicts of interest within the advisory process. The PCAC is an expert body that advises the FDA on compounding matters, and it is unusual for the agency to go against the committee’s recommendations, though it has happened at least once before.
The specific peptides approved for compounding on Thursday include BPC-157, a peptide promoted for healing injuries and gut health; KPV, which has been studied for anti-inflammatory properties; TB-500, a synthetic thymosin beta-4 used for tissue repair; and MOTS-c, a mitochondrial-derived peptide linked to metabolic regulation. None of these drugs have received FDA approval for any medical indication.
The FDA now faces the decision of whether to finalize the PCAC’s recommendations. If the agency adopts them, compounding pharmacies would be allowed to produce and dispense these peptides, potentially increasing patient access. However, critics warn that the move could expose consumers to products with unknown safety and efficacy profiles.
The vote on Thursday came in the context of a broader debate over the regulation of peptides, which have surged in popularity as wellness and longevity aids. Health secretary Robert F. Kennedy Jr. has been a vocal supporter of expanding access to alternative treatments, and his position aligns with the committee’s recommendation.
The FDA has historically been cautious about allowing compounding of unapproved drugs, citing concerns about quality control and patient safety. The PCAC’s unusual vote, combined with the disclosure of industry ties among supporters, adds a layer of controversy to the proceeding.
Further votes on additional peptide compounds are expected on Friday. The FDA has not indicated how quickly it will issue a final decision on the recommendations. The agency has until a statutory deadline to respond, but the timeline remains uncertain.
Observers note that the panel’s decision could set a precedent for how the FDA handles other unapproved peptides in the future. The agency’s response will be closely watched by both the peptide industry and public health advocates who have raised alarms about the lack of rigorous testing for these drugs.
Peptides referenced: BPC-157, TB-500, MOTS-c, Thymosin Beta-4.
Related reading: GLP-1 Claims, Hidden Fees, and Made in USA Examined in New Advisory, Lilly Plans FDA Filing for Retatrutide After New Phase 3 Data, FDA panel to weigh peptide compounding amid conflict concerns, Peptides Gain Favor on First Day of FDA Compounding Meeting.